Our Pricing

How to Change From Mounjaro to Wegovy: Clinical Switch Guide for UK Patients

Many UK patients are considering a change from Mounjaro to Wegovy due to cost differences, supply availability, or clinical recommendations from their prescriber. Both medications are highly effective GLP-1 receptor agonists used for weight management, but they contain different active ingredients—tirzepatide in Mounjaro and semaglutide in Wegovy—which means switching requires careful clinical planning. This guide, written by our UK-registered clinical team at Cured Pharmacy, explains the safe transition process, dose equivalence, expected outcomes, and potential cost savings when you switch between these two leading weight loss treatments.

Why Patients Change From Mounjaro to Wegovy in the UK

The decision to change from Mounjaro to Wegovy is becoming increasingly common among UK patients, driven primarily by three factors: cost considerations, medication availability, and individual treatment response. Wegovy costs from £124.99 per month at Cured Pharmacy compared to Mounjaro at £124.99 representing a potential saving of over £124.99 annually for patients on long-term treatment [1]. This price difference is significant for those funding their own weight management therapy outside the NHS.

Supply chain factors also influence switching decisions. While both medications have experienced intermittent shortages in the UK, their availability patterns differ, and some patients switch temporarily or permanently based on which treatment their pharmacy can reliably source. Additionally, clinical response varies between individuals—while both are GLP-1 receptor agonists, Mounjaro's dual GIP/GLP-1 mechanism and Wegovy's pure GLP-1 action may suit different patient profiles. Some patients experience better tolerability or efficacy with one medication over the other, and a supervised switch allows exploration of the alternative under medical guidance [2].

Clinical Differences: Understanding the Change From Mounjaro to Wegovy

When you change from Mounjaro to Wegovy, you're switching between two distinct pharmacological agents, despite their shared therapeutic goal. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, whilst Wegovy contains semaglutide, a selective GLP-1 receptor agonist. In the SURPASS-2 head-to-head trial, tirzepatide demonstrated superior weight loss compared to semaglutide, with patients losing an average of 12.4kg on tirzepatide 15mg versus 6.2kg on semaglutide 1mg over 40 weeks [3]. However, Wegovy's STEP trials showed impressive results in their own right, with average weight loss of 15% body weight over 68 weeks at the 2.4mg maintenance dose [4].

The key clinical consideration when switching is that these medications are not dose-equivalent. Mounjaro is administered weekly in doses ranging from 2.5mg to 15mg, while Wegovy uses a different dosing schedule from 0.25mg up to 2.4mg weekly. The transition requires careful prescriber assessment to determine the appropriate starting dose of Wegovy based on your current Mounjaro dose, treatment duration, and individual response. Most UK prescribers recommend a brief washout period or direct transition depending on your clinical circumstances, which our pharmacist team can discuss during your online consultation.

Mechanism of Action Comparison

Mounjaro's dual receptor activity means it stimulates both GLP-1 receptors (reducing appetite and slowing gastric emptying) and GIP receptors (which may enhance insulin secretion and fat metabolism). Wegovy works exclusively through GLP-1 receptor activation, providing potent appetite suppression and improved glycaemic control. When you change from Mounjaro to Wegovy, you may notice subtle differences in side effect profile or hunger control, though both medications are highly effective for weight management when used as part of a comprehensive lifestyle programme [1].

Safe Dosing Protocol for the Change From Mounjaro to Wegovy

The transition when you change from Mounjaro to Wegovy must follow a medically supervised protocol to minimise side effects and maintain treatment efficacy. There is no direct dose conversion between tirzepatide and semaglutide, as they are pharmacologically distinct compounds. UK prescribers typically recommend one of two approaches: either completing a one-week washout period after your last Mounjaro dose before starting Wegovy at the initial 0.25mg dose, or transitioning directly to a mid-range Wegovy dose if you've been on higher-dose Mounjaro for several months.

For patients switching from Mounjaro 2.5mg or 5mg, the standard approach is to begin Wegovy at the starter dose of 0.25mg weekly for four weeks, then escalate following the standard titration schedule (0.5mg, 1mg, 1.7mg, to 2.4mg maintenance) [4]. Patients on higher Mounjaro doses (10mg or 15mg) may be able to start Wegovy at 0.5mg or 1mg after prescriber assessment, potentially shortening the titration period. This individualised approach, available through Cured Pharmacy's online consultation, ensures your switch is both safe and effective whilst minimising gastrointestinal side effects commonly associated with GLP-1 therapies.

Timing Your Switch for Optimal Results

The optimal timing for your change from Mounjaro to Wegovy depends on your current treatment phase. If you're still in the titration phase on Mounjaro (doses below 10mg), switching earlier may be more straightforward as your body hasn't adapted to the highest tirzepatide doses. Patients on maintenance doses of Mounjaro 12.5mg or 15mg should expect a more gradual transition, as Wegovy's maximum 2.4mg dose represents a different receptor engagement profile. Our UK-registered prescribers will assess your treatment history, weight loss progress, and any side effects experienced to recommend the safest switching timeline during your consultation.

Expected Outcomes When You Change From Mounjaro to Wegovy

Clinical evidence suggests that patients who change from Mounjaro to Wegovy can maintain significant weight loss, though individual results vary based on adherence, lifestyle factors, and biological response. In real-world UK clinical practice, patients switching from tirzepatide to semaglutide typically continue to lose weight or maintain their achieved weight loss, provided they reach the full maintenance dose of Wegovy 2.4mg and continue their dietary and exercise modifications [2]. Some patients report comparable appetite suppression between the two medications, whilst others notice differences in hunger control or side effect profiles.

It's important to set realistic expectations: while Mounjaro demonstrated higher average weight loss in direct comparison trials, Wegovy remains one of the most effective weight management medications available, with STEP trial participants losing an average of 15% of their body weight over 68 weeks [4]. When you change from Mounjaro to Wegovy, you're not switching to a less effective treatment—you're transitioning to a proven GLP-1 therapy with extensive clinical evidence, often at a significantly lower cost. Most patients successfully maintain their weight loss trajectory after switching, particularly when supported by ongoing clinical monitoring and lifestyle counselling.

Cost Savings: Financial Benefits of the Change From Mounjaro to Wegovy

The financial advantage of switching from Mounjaro to Wegovy is substantial for UK patients funding their own treatment. At Cured Pharmacy, Wegovy starts from £124.99 per month compared to Mounjaro at £124.99 representing a monthly saving of £124.99 or £124.99 annually. For patients on long-term weight management therapy—often 12-24 months or longer—these savings accumulate significantly whilst maintaining access to a clinically proven, MHRA-licensed GLP-1 medication. New patients can save an additional £20 off their first order with code Weightlossnew, reducing the initial Wegovy cost to just £124.99.

When you change from Mounjaro to Wegovy at Cured Pharmacy, you benefit from transparent upfront pricing with no hidden consultation fees or subscription traps. Our prices include the medication, UK prescriber assessment, and discreet home delivery. The cost difference between these two treatments doesn't reflect a difference in quality or legitimacy—both are genuine, UK-licensed medications dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). The price variation reflects different manufacturer pricing strategies and market positioning, allowing cost-conscious patients to access highly effective weight management therapy at the cheapest UK price available.

Long-Term Treatment Cost Comparison

Over a typical 12-month weight management programme, the cumulative savings from switching to Wegovy can exceed £124.99 compared to remaining on Mounjaro. For patients who require 18-24 months of treatment to reach and consolidate their goal weight—as recommended in NICE guidelines for obesity pharmacotherapy—the total saving approaches £124.99-£124.99. These figures make the change from Mounjaro to Wegovy an economically sound decision for many UK patients, particularly those without private medical insurance coverage for weight management medications.

How to Change From Mounjaro to Wegovy Through Cured Pharmacy

Switching your treatment at Cured Pharmacy is straightforward and medically supervised. Begin by completing our online clinical assessment, which takes under three minutes and asks about your current Mounjaro dose, treatment duration, weight loss progress, any side effects, and your medical history. Our UK-registered prescribers review every assessment individually—this isn't an automated process—and will determine whether Wegovy is clinically appropriate for you and what starting dose is safest based on your current tirzepatide regimen. If approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy and delivered discreetly to your home, typically within 24-48 hours.

During your consultation, be specific about your current Mounjaro dose and how long you've been taking it, as this directly influences the recommended Wegovy starting dose. If you've experienced significant side effects on Mounjaro—such as persistent nausea or gastrointestinal issues—mention these, as they may affect your titration schedule on Wegovy. Our clinical team can also advise on the optimal timing for your switch, whether you should complete a washout period, and how to manage the transition to minimise any temporary changes in appetite control. Ongoing support is available through our pharmacy team if you have questions during your first weeks on Wegovy after making the change from Mounjaro to Wegovy.

Ongoing Monitoring and Prescription Renewals

After your initial switch, you'll need regular prescription renewals as you progress through Wegovy's dose escalation schedule. Cured Pharmacy makes this simple with reminder notifications before your medication runs out and streamlined repeat consultation processes. Our prescribers monitor your progress at each renewal, adjusting your dose according to the standard titration protocol or your individual response. This ongoing clinical oversight ensures your change from Mounjaro to Wegovy is not just a one-time switch, but a properly managed transition with continuous medical support throughout your weight management journey.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, parallel-group, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.